Despite an overall decrease in tobacco use lung cancer (80-85% of which is non-small-cell lung
cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide.
Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage
tumors which can usually be successfully treated with a combination of surgery radiotherapy
and chemotherapy and in some cases targeted therapy. However most patients with NSCLC still
present with advanced or metastatic disease. For these patients initial therapy is guided by
the tumor's molecular characteristics and patient's performance status. Targeted therapies have
significantly improved clinical outcomes and for some patients with no targetable genetic
alterations immunotherapy has demonstrated significant overall survival benefit. This
insightful guide is designed to bring you up to speed with the latest developments and is
important reading for all health professionals and medical trainees working in this fast-moving
field. Table of Contents: -Prevention and screening -Diagnosis and staging -Surgery
-Radiotherapy -Systemic therapy in non-metastatic NSCLC -Systemic therapy in advanced-stage
metastatic disease without a molecular driver -Personalized treatment in advanced NSCLC
-Oligometastatic disease and brain metastases
